New JAK Inhibitors

Catalog No. Product Name Information
E5866 Cenacitinib Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.
E4720 Flonoltinib Flonoltinib (JAK2/FLT3-IN-1) is a potent and selective dual inhibitor of JAK2 and FLT3, with IC50 of of 0.8, 1.4, and 15 nM against JAK2, JAK2V617F, and FLT3, respectively, in in vitro kinase assays. It also inhibits cell proliferation and induces G2/M cell cycle arrest and apoptosis in Hemophagocytic Lymphohistiocytosis (HLH) patients' CD8+T cells, CTLL2 cells, and RAW 264.7 cells.
E8276 Golidocitinib 1-hydroxy-2-naphthoate Golidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
S7640 Lestaurtinib Lestaurtinib (CEP-701, KT-5555) is a derivative of the indolocarbazole K252 and a staurosporine analog. It is an orally active inhibitor of receptor protein tyrosine kinases (RPTKs), which inhibits FLT3 and Trk, with an IC50 of 3 nM and < 25 nM, respectively. It also inhibits JAK2 with an IC50 of 0.9 nM.
E5818 Fedratinib hydrochloride hydrate Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate, SAR 302503 hydrochloride hydrate) is a small-molecule, ATP-competitive inhibitor of JAK2 with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. It induces cancer cell apoptosis and has potential for efficacious treatment of JAK2V617F-associated myeloproliferative disease.
All JAK Inhibitors